Payment overview · 2025
General Payments
$583.10
19 reported records · 3 companies
Healthcare provider profile · identity verified
Jivan Melikian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · GLENDALE, CA · NPI 1285705905
Verified facts
What the public records show
CMS Open Payments records show Jivan Melikian, M.D. received $583.10 in general payments during 2025 across 19 reported records.
Abbott Laboratories accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 533 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 462 claims for Nexlizet by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $341.09 | 58.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $164.56 | 28.2% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.45 | 13.3% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $583.10 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $341.09 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $164.56 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.45 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 533 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
533 | 102 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
462 | 66 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1211 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1088 | 170 |
| Furosemide | Furosemide | 915 | 153 |
| Clopidogrel | Clopidogrel Bisulfate | 558 | 82 |
| Jardiance | Empagliflozin | 533 | 102 |
| Nitroglycerin | Nitroglycerin | 531 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 516 | 77 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 462 | 66 |
| Ezetimibe | Ezetimibe | 334 | 56 |
| Valsartan | Valsartan | 289 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 270 | 42 |
| Eliquis | Apixaban | 268 | 40 |
| Entresto | Sacubitril/Valsartan | 262 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 240 | 28 |
| Carvedilol | Carvedilol | 236 | 38 |
| Losartan Potassium | Losartan Potassium | 227 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 219 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 28 |
| Xarelto | Rivaroxaban | 203 | 32 |
| Farxiga | Dapagliflozin Propanediol | 200 | 27 |
| Vascepa | Icosapent Ethyl | 177 | 28 |
| Atenolol | Atenolol | 156 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 136 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 110 | 20 |
| Repatha Sureclick | Evolocumab | 96 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 90 | 20 |
| Sotalol | Sotalol Hcl | 78 | 17 |
| Spironolactone | Spironolactone | 78 | 13 |
| Famotidine | Famotidine | 77 | 14 |
| Omeprazole | Omeprazole | 77 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 60 | 16 |
| Cilostazol | Cilostazol | 59 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Ranolazine Er | Ranolazine | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Colchicine | Colchicine | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $583.10 · 19 records | Abbott Laboratories | JARDIANCE, NEXLETOL, PRESSUREWIRE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error